Cardiome Pharma announced a set of changes to their senior management team.
Commenting on the changes, William Hunter, MD, CEO and President of Cardiome, said “Cardiome is a very different company than it was even a few years ago. We are no longer focused on a single drug and are now a diversified Company selling multiple medicines. We have built a fully integrated pharmaceutical company that sells its products into almost every major pharmaceutical market in the world outside of the United States. We have licensed and acquired compelling medicines and expect to add more products in the foreseeable future via our robust business development pipeline. We feel that we are on the cusp of significant operational momentum and our Team will evolve as necessary in order to maximize the Company’s potential.”
Changes to the Management Team:
- Justin Renz joins Cardiome as its new Chief Financial Officer (CFO),
- Jennifer Archibald, Cardiome’s current CFO, has been appointed to the position of Chief Business Operations Officer,
- David Dean, Cardiome’s VP Business Development and Investor Relations, has been appointed to the position of Chief Business Development Officer,
- Hugues Sachot, Cardiome’s SVP Commercial, has been appointed to the position of Chief Commercial Officer.